Christopher F Rowley

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Improvement in allele-specific PCR assay with the use of polymorphism-specific primers for the analysis of minor variant drug resistance in HIV-1 subtype C
    Christopher F Rowley
    Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Lowry Building, Suite GB, 110 Francis Street, Boston, MA 02215, USA
    J Virol Methods 149:69-75. 2008
  2. ncbi Ultrasensitive detection of minor drug-resistant variants for HIV after nevirapine exposure using allele-specific PCR: clinical significance
    Christopher F Rowley
    Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    AIDS Res Hum Retroviruses 26:293-300. 2010
  3. ncbi Abacavir alters the transcription of inflammatory cytokines in virologically suppressed, HIV-infected women
    Iain J MacLeod
    Harvard School of Public Health AIDS Initiative, Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA 02115, USA
    J Int AIDS Soc 15:17393. 2012
  4. ncbi Reduced viral replication capacity of human immunodeficiency virus type 1 subtype C caused by cytotoxic-T-lymphocyte escape mutations in HLA-B57 epitopes of capsid protein
    Christian L Boutwell
    Department of Immunology and Infectious Diseases, Harvard School of Public Health AIDS Initiative, Harvard School of Public Health, 651 Huntington Avenue, Boston, Massachusetts 02115, USA
    J Virol 83:2460-8. 2009
  5. ncbi Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis
    Melissa Farmer Miller
    Division of Cancer Prevention, Cancer Prevention Fellowship Program, National Cancer Institute, Bethesda, Maryland, USA
    Clin Infect Dis 41:713-20. 2005

Collaborators

Detail Information

Publications5

  1. ncbi Improvement in allele-specific PCR assay with the use of polymorphism-specific primers for the analysis of minor variant drug resistance in HIV-1 subtype C
    Christopher F Rowley
    Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Lowry Building, Suite GB, 110 Francis Street, Boston, MA 02215, USA
    J Virol Methods 149:69-75. 2008
    ..15-1.36% and 5.20-5.71% resistance for the same 1% and 5% samples. The results demonstrate the need to account for sequence polymorphisms when designing and implementing this highly specific assay...
  2. ncbi Ultrasensitive detection of minor drug-resistant variants for HIV after nevirapine exposure using allele-specific PCR: clinical significance
    Christopher F Rowley
    Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    AIDS Res Hum Retroviruses 26:293-300. 2010
    ..These data suggest a clinical role for highly sensitive assays to detect and quantify resistant viruses at low frequencies...
  3. ncbi Abacavir alters the transcription of inflammatory cytokines in virologically suppressed, HIV-infected women
    Iain J MacLeod
    Harvard School of Public Health AIDS Initiative, Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA 02115, USA
    J Int AIDS Soc 15:17393. 2012
    ..Abacavir (ABC) may be associated with a small, increased risk of myocardial infarction in HIV-infected adults, possibly related to cytokine-mediated inflammation...
  4. ncbi Reduced viral replication capacity of human immunodeficiency virus type 1 subtype C caused by cytotoxic-T-lymphocyte escape mutations in HLA-B57 epitopes of capsid protein
    Christian L Boutwell
    Department of Immunology and Infectious Diseases, Harvard School of Public Health AIDS Initiative, Harvard School of Public Health, 651 Huntington Avenue, Boston, Massachusetts 02115, USA
    J Virol 83:2460-8. 2009
    ....
  5. ncbi Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis
    Melissa Farmer Miller
    Division of Cancer Prevention, Cancer Prevention Fellowship Program, National Cancer Institute, Bethesda, Maryland, USA
    Clin Infect Dis 41:713-20. 2005
    ..Future research should examine whether an impaired immunologic response corresponds with meaningful virologic and clinical outcomes...